Novo Nordisk A/S

New York Stock Exchange
Back to all articles
Somewhat Bearish -25

Novo Nordisk's September Tightrope: A Cardiology Setback, a Paediatric Milestone, and a Buyback That Keeps Running

AI-generated analysis

📉 Novo Nordisk stock drops 30% from its January high, trading at €38.41 despite a massive share buyback program that has spent roughly 9 billion kroner.

💊 The company halted late-stage trials for Ziltivekimab in heart failure due to a low probability of success following a failed cardiovascular outcome readout.

👶 Novo Nordisk achieved a pediatric milestone with the STEP Young trial, showing 40.4% of children under 12 treated with Wegovy no longer met obesity definitions.

💊 The oral version of Wegovy launched in Germany as the first EU market for the tablet formulation, though Citi notes slowing new prescription trends for key GLP-1 products.

🌏 Novo Nordisk hosted the inaugural 'Novo Group India Day' in Bengaluru, marking the region's strategic importance as healthcare spending accelerates.

📅 The company has a 15 billion kroner buyback envelope running until early February 2027, with management signaling confidence despite weak market tape.

⚠️ Citi maintains a sell rating with a price target of 265 Danish kroner, citing slowing prescription trends and a thinning pipeline beyond GLP-1.

📊 The stock trades significantly below its 50-day moving average of €41.44, requiring a reclaim of this level for any technical recovery to gain credibility.

🗓️ Management must articulate how it intends to fill the Ziltivekimab-shaped hole in its pipeline ahead of the September 21 capital markets day.

Bullish Signals
  • Novo Nordisk completed a significant share buyback, accumulating 32,034,179 B-shares at an average price of 281.63 Danish kroner with a total outlay of roughly 9 billion kroner.
  • The Phase 3 STEP Young trial demonstrated that 40.4% of treated children under 12 no longer met the definition of obesity by the study's end, opening a largely untapped age group.
  • Novo Nordisk launched the oral version of Wegovy in Germany, marking the first EU market for the tablet formulation and diversifying revenue away from injectables.
  • The company hosted the inaugural 'Novo Group India Day' in Bengaluru, underscoring its geographic ambitions as India is the only country outside Denmark where all four Novo entities operate.
Risk Factors
  • Novo Nordisk's stock dropped 30% from its January high and has shed 13% since the start of the year, trading well below the 50-day moving average.
  • The company halted two late-stage trials of Ziltivekimab in heart failure following a failed cardiovascular outcome readout, effectively hollowing out a growth driver.
  • Citi maintains a sell rating with a price target of 265 Danish kroner based on weekly IQVIA prescription tracking showing slowing new-prescription trends for key GLP-1 obesity products.
  • The market perceives the company's growth story as standing on a narrower foundation than assumed due to a thinning pipeline beyond GLP-1 and potential revenue slowdowns.
Full Analysis
Novo Nordisk faces significant market pressure with its stock trading 30% below its January high, despite an aggressive share buyback program that has spent roughly 9 billion kroner. The company's equity has shed 13% year-to-date, currently trading at €38.41, well below the 50-day moving average of €41.44. Management continues to signal confidence through relentless repurchases, accumulating over 32 million B-shares, yet technical analysts view the chart as damaged due to persistent selling pressure. The primary driver of investor nervousness is a major setback in its cardiology pipeline, specifically the decision to halt late-stage trials for Ziltivekimab in heart failure. An independent committee cited a low probability of success following a failed cardiovascular outcome readout in July, effectively hollowing out a potential growth driver beyond its core GLP-1 franchise. Only one study remains active for post-heart-attack patients, with results not expected until the first half of 2027. Despite the cardiology headwinds, Novo Nordisk achieved a milestone in pediatrics with the Phase 3 STEP Young trial showing that 40.4% of children under 12 treated with Wegovy no longer met obesity definitions by the study's end. Concurrently, the company launched its oral Wegovy tablet in Germany, though Citi notes slowing new prescription trends for key GLP-1 products. The upcoming September 21 capital markets day will be critical as management addresses how to fill the pipeline gap left by the cardiology setbacks. Strategic expansion continues with the inaugural 'Novo Group India Day' highlighting the region's importance as healthcare spending accelerates outside Denmark. While the buyback program aims to support the stock price, the market remains cautious about a thinning pipeline beyond GLP-1 and potential revenue slowdowns. The elevated volatility reflects the tension between management's undervaluation thesis and external concerns regarding the company's growth foundation.